Back to search

Article

Immune Gene Signature as a Predictor of CDK4/6 Inhibitor Response in HR+/HER2– Breast Cancer

2025-03-11

Abstract excerpt

<title>Abstract</title> <p><bold>Background: </bold>Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) are a standard treatment for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC). However, reliable predictive biomarkers for treatment efficacy remain an unmet clinical need. <bold>Methods: </bold>A cohort of HR+/HER2– ABC patients (n=100) treated...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6f5753c0-6e89-55e4-a764-94d6f0f498ef
DOI
10.21203/rs.3.rs-6129690/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Immune Gene Signature as a Predictor of CDK4/6 Inhibitor Response in HR+/HER2– Breast CancerDOI 10.21203/rs.3.rs-6129690/v1
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and TranscriptomicsSemantic proximity
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN signalingSemantic proximity
Identification of immune-related biomarkers for predicting neoadjuvant chemotherapy sensitivity in HER2 negative breast cancer via bioinformatics analysisSemantic proximity
Deregulated Immune Pathway Associated with Palbociclib Resistance in Preclinical Breast Cancer Models: Integrative Genomics and Transcriptomics.Semantic proximity
Identification of A 10-Gene Signature To Predict Efficacy of Neoadjuvant Therapy in Patients With HER2 Positive Breast Cancer.Semantic proximity
Integrated immune-related gene signature predicts clinical outcome for patients with Luminal B breast cancerSemantic proximity
Identification of immune subtypes and response prediction to immune-checkpoint inhibitors for MDM4 gain/amplification luminal A type breast cancerSemantic proximity
Identification of a 10-Gene Signature Model to Predict Efficacy of Neoadjuvant Therapy in Patients With HER2&nbsp;Positive Breast Cancer.Semantic proximity
Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer.Semantic proximity
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancer.Semantic proximity
Sequencing analysis reveals evidence of immune activation in advanced HER2 negative breast cancer responders treated with entinostat + nivolumab + ipilimumabSemantic proximity
Immune Effective Score As A Predictor Of Response To Neoadjuvant Trastuzumab Therapy And A Prognostic Indicator For HER2-positive Breast CancerSemantic proximity
Select a neighboring publication to make it the new centre.